The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: A cohort study in the United Kingdom

International Journal of Obesity

Volumn 39, Issue 9, 2015, Pages 1359-1364

  Hayes, J F ^a   Bhaskaran, K ^b   Batterham, R ^a   Smeeth, L ^b   Douglas, I ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM; WEIGHT REDUCTION; CHEMICALLY INDUCED; COMPLICATION; CONTRAINDICATIONS; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SAFETY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; COHORT STUDIES; CYCLOBUTANES; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OBESITY; PATIENT SAFETY; PATIENT SELECTION; PRACTICE PATTERNS, PHYSICIANS'; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; UNITED KINGDOM;

EID: 84941192413     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.86     Document Type: Article

References (24)

1. National Institute for Health and Care Excellence Clinical Guideline 43: Obesity: the Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. NICE: London, UK, 2006.
2. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010; 340: c824.
3. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
4. Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf 2011; 34: 641-650.
5. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530.
6. Czernichow S, Batty GD. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obesity Facts 2010; 3: 155-156.
7. Sayburn A. Withdrawal of sibutramine leaves European doctors with just one obesity drug. BMJ 2010; 340: c477.
8. Scheen AJ. Controversy about the cardiovascular safety of sibutramine. Drug Saf 2010; 33: 615-618.
9. Douglas IJ BK, Batterham R, Smeeth L. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. Br J Clin Pharmacol 2015; 79: 1020-1027.
10. Clinical Practice Research Datalink. http://www. cprd. com.
11. Williams T, Van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3: 89-99.
12. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM 1998; 91: 445-452.
13. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425.
14. Benson T. The history of the Read codes: the inaugural James Read Memorial Lecture 2011. Inform Prim Care 19: 173-182.
15. The Office for National Statistics. Key Health Statistics from General Practice 1998. The Office for National Statstics: London, UK, 2000.
16. London School of Hygiene and Tropical Medicine. http://www. lshtm. ac. uk/study/ applicants/shortcourses/practical-pharmacoepidemiology-gprd-background. pdf.
17. Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 2010; 10: 321-334.
18. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med 2010; 29: 2920-2931.
19. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
20. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319: 1492-1495.
21. StataCorp. Stata Statistical Software. StataCorp LP: College Station, TX, USA, 2009.
22. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Rodríguez LAG, Ruigómez A, Meier CR et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689.
23. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes 2007; 31: 1567-1570.
24. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 2013; 346.